Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
Melinda Gooderham, Kim Papp, Melinda Gooderham, Kim Papp
Abstract
Phosphodiesterase (PDE) 4 participates in regulating the inflammatory response by degrading cyclic adenosine 3'5'-monophosphate (cAMP), a key second messenger. Inhibition of PDE4 increases the intracellular cAMP level, which in turn results in a reduction in inflammatory mediators and an increase in anti-inflammatory mediators. Immune-modulating effects of PDE4 inhibitors have been investigated in a number of inflammatory conditions, such as asthma, atopic dermatitis, chronic obstructive pulmonary disease, Behçet’s disease, psoriasis, and psoriatic arthritis. Apremilast, a selective PDE4 inhibitor, has been shown to block the production of pro-inflammatory cytokines (interferon-γ, tumor necrosis factor-α, interleukin [IL]-12, IL-17, and IL-23), which are the key players in the pathogenesis of psoriasis. Increased intracellular cAMP levels result in a range of anti-inflammatory effects on numerous cell lines. A decrease in proinflammatory activity has been shown to result in a reduced psoriasiform response in preclinical in vivo models of psoriasis, and reduction of biologic activity in a pilot study in humans. The efficacy and safety of apremilast in the treatment of psoriasis have been demonstrated in phase II and III clinical trials. Apremilast demonstrated efficacy in reducing the severity of moderate to severe plaque psoriasis. Treatment with apremilast was well tolerated, with generally mild gastrointestinal complaints, which occurred early in the course of the treatment and resolved over time, and there was no requirement for laboratory test monitoring. These results make apremilast an attractive therapeutic option for plaque psoriasis.
Figures
References
- Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583–1590. doi: 10.1016/j.bcp.2012.01.001.
- Schafer PH, Parton A, Capone LH, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016–2029. doi: 10.1016/j.cellsig.2014.05.014.
- Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn’s disease. J Am Acad Dermatol. 2003;48(6):805–821. doi: 10.1067/mjd.2003.540.
- Bäumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007;6(1):17–26. doi: 10.2174/187152807780077318.
- Serezani CH, Ballinger MN, Aronoff DM, et al. Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol. 2008;39(2):127–132. doi: 10.1165/rcmb.2008-0091TR.
- Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behçet’s syndrome—a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510–1518. doi: 10.1056/NEJMoa1408684.
- Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159:842–855. doi: 10.1111/j.1476-5381.2009.00559.x.
- Gottleib AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008;24(5):1529–1538. doi: 10.1185/030079908X301866.
- Man HW, Schafer P, Wong LM, et al. Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihy dro-1 H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem. 2009;52:1522–1524. doi: 10.1021/jm900210d.
- Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005;10(22):1503–1519. doi: 10.1016/S1359-6446(05)03622-6.
- Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol. 2013;27(3):e376–e383. doi: 10.1111/j.1468-3083.2012.04716.x.
- Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomized controlled trial. Lancet. 2012;380(9843):738–746. doi: 10.1016/S0140-6736(12)60642-4.
- Strand V, Hu A, Day R, et al. Improved quality of life with apremilast (APR) in the treatment of psoriasis: results from a phase IIb randomized controlled study (abstract no. P3337). J Am Acad Dermatol. 2011;64:AB154.
- Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, Schafer PH, Krueger JG. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol. 2013;12(8):888–897.
- Papp K, Reich K, Leonardi C, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: results from the randomized treatment withdrawal phase of a phase 3, randomized, controlled trial (ESTEEM 1) [poster no. 8359]. In: Presented at the 72nd Annual Meeting of the American Academy of Dermatology; Denver; March 21–25, 2014.
- Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015. doi:10.1111/bjd.14164.
- Reich K, Soung J, Gooderham M, et al. Efficacy and safety of apremilast or etanercept compared with placebo in patients with moderate to severe psoriasis. In: Presented at the 73rd Annual Meeting of the American Academy of Dermatology; San Francisco; March 20–24, 2015.
- Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020–1026. doi: 10.1136/annrheumdis-2013-205056.
- Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015;42;479–88.
- Cutolo M, Myerson GE, Fleischmann RM, et al. Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2) [presentation no. 815]. In: Presented at the 2013 ACR/ARHP Annual Meeting; San Diego; October 26–30, 2013.
- Edwards CJ, Blanco FJ, Crowley J, et al. Long-term (52-Week) Results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement (PALACE 3) [poster no. 311]. In: Presented at Presented at the 2013 ACR/ARHP Annual Meeting; San Diego; October 26–30, 2013.
- Edwards CJ, Wells AF, Adebajo AO, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-Week) improvements in enthesitis or dactylitis in patients with psoriatic arthritis: results from the PALACE 4 phase 3, randomized, controlled trial [poster no. SAT0389]. In: Presented at the Annual European Congress of Rheumatology (EULAR); Paris; June 11–14, 2014.
- Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of two phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2015 (In press).
- Crowley J, Cather J, Gooderham M, et al. Apremilast in moderate to severe plaque psoriasis: 32-Week results in patients with nail, scalp, and palmoplantar involvement (ESTEEM 2) [poster no. P1687]. In: Presented at the 23rd Congress of the European Academy of Dermatology and Venereology; Amsterdam; October 8–12, 2014.
- Armstrong AW, Griffiths CEM, Tencer T, et al. Effect of apremilast on patient-reported outcomes in patients with moderate to severe plaque psoriasis in the ESTEEM 1 trial [poster no. P1691]. In: Presented at the 23rd Congress of the European Academy of Dermatology and Venereology; Amsterdam; October 8–12, 2014.
- Papp K, Zhang F, Tencer T, et al. The impact of apremilast therapy on work productivity among patients with moderate to severe plaque psoriasis: pooled analysis of 2 phase 3 studies [poster no. 1151]. In: Presented at the 73rd Annual Meeting of the American Academy of Dermatology; San Francisco; March 20–24, 2015.
- Crowley J, Gooderham M, Wasel N, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with nail, scalp, and palmoplantar psoriasis: 52-week results from the ESTEEM 2 trial [poster no. 894]. In: Presented at the 73rd Annual Meeting of the American Academy of Dermatology; San Francisco; March 20–24, 2015.
- Reich K, Papp K, Leonardi C, et al. Long‐term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: results from a Phase III, randomized, controlled trial (ESTEEM 1) [poster no. 8296]. In: Presented at the 72nd Annual Meeting of the American Academy of Dermatology; Denver; March 21–25, 2014.
- Papp KA, Reich K, Sobell JM, et al. Two-year safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: results from a phase 3, randomized, controlled trial (ESTEEM 1) [poster no. 1055]. In: Presented at: the 73rd Annual Meeting of the American Academy of Dermatology; San Francisco; March 20–24, 2015.
- Celgene Corporation. Otezla (apremilast): full prescribing information. . Accessed Sept 2014.
- Reich K, Sobell J, Stevens RM, et al. Change in weight with apremilast, an oral phosphodiesterase 4 inhibitor: pooled analysis of the ESTEEM 1 and ESTEEM 2 trials [poster no. P1690]. Presented at the 23rd Congress of the European Academy of Dermatology and Venereology; Amsterdam; October 8–12, 2014.
- Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891–895.
- Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;11:CD002309.
- Hayes J, Koo J. Psoriasis: depression, anxiety, smoking, and drinking habits. Dermatol Ther. 2010;23(2):174–180. doi: 10.1111/j.1529-8019.2010.01312.x.
- Menter A, Paul C, Stevens RM, et al. Psychiatric disorders and depression incidence with apremilast, an oral phosphodiesterase 4 inhibitor: pooled analysis of the ESTEEM 1 and ESTEEM 2 trials [poster no. P1689]. Presented at the 23rd Congress of the European Academy of Dermatology and Venereology; Amsterdam; October 8–12, 2014.
- Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) Br J Dermatol. 2008;158(3):558–566. doi: 10.1111/j.1365-2133.2007.08315.x.
- Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1) Br J Dermatol. 2011;165(5):1109–1117. doi: 10.1111/j.1365-2133.2011.10615.x.
- Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011;365(17):1586–1596. doi: 10.1056/NEJMoa1010858.
Source: PubMed